Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 17, 2020 - Issue 6
Submit an article Journal homepage
1,646
Views
5
CrossRef citations to date
0
Altmetric
Editorial

Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix

Scott Caroena Clinical Department, EpicentRx, Inc, La Jolla, CA, USAView further author information
,
Bryan Oronskya Clinical Department, EpicentRx, Inc, La Jolla, CA, USACorrespondence[email protected]
View further author information
,
Corey Cartera Clinical Department, EpicentRx, Inc, La Jolla, CA, USAView further author information
,
Michelle Lybecka Clinical Department, EpicentRx, Inc, La Jolla, CA, USAView further author information
,
Arnold Oronskyb Clinical Department, InterWest Partners, Menlo Park, CA, USAView further author information
&
Tony Reida Clinical Department, EpicentRx, Inc, La Jolla, CA, USAView further author information
Pages 741-742 | Received 02 Feb 2020, Accepted 24 Apr 2020, Published online: 30 Apr 2020

References

  • Oronsky B, Scicinski J, Ning S, et al. Rockets, radiosensitizers, and RRx-001: an origin story part I. Discov Med. 2016 Mar;21(115):173–180.
  • Oronsky B, Reid TR, Larson C, et al. REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer. Future Oncol. 2019 Oct;15(30):3427–3433.
  • Oronsky B, Reid TR, Oronsky A, et al. Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells. Oncotarget. 2018 May 4;9(34):23439–23442.
  • Cabrales P. RRx-001 acts as a dual small molecule checkpoint inhibitor by downregulating CD47 on cancer cells and SIRP-α on monocytes/macrophages. Transl Oncol. 2019 Apr;12(4):626–632.
  • Kim MM, Parmar H, Cao Y, et al. Whole brain radiotherapy and RRx-001: two partial responses in radioresistant melanoma brain metastases from a Phase I/II clinical trial: a TITE-CRM Phase I/II clinical trial. Transl Oncol. 2016 Apr;9(2):108–113.
  • Das DS, Ray A, Das A, et al. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia. 2016 Nov;30(11):2187–2197.
  • Oronsky B, Ma PC, Morgensztern D, et al. Nothing But NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017 Dec;19(12):991–1002.
  • Oronsky B, Caroen S, Zeman K, et al. A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001. Clin Med Insights Oncol. 2016 Nov 6;10(105–108). DOI:10.4137/CMO.S40429.
  • Oronsky B, Reid TR, Oronsky A, et al. What’s New in SCLC? A review. Neoplasia. 2017 Oct;19(10):842–847.
  • Reid T, Oronsky B, Scicinski J, et al. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep;16(9):1133–1142.
  • Scicinski J, Fisher G, Carter C, et al. The development of RRx-001, a novel nitric-oxide-mediated epigenetically active anticancer agent. Redox Biol. 2015 Aug;5:422.
  • Bautista DM, Jordt SE, Nikai T, et al. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell. 2006;124(6):1269–1282.
  • Holthusen H, Arndt JO. Nitric oxide evokes pain at nociceptors of the paravascular tissue and veins in humans. J Physiol. 1995 Aug 15;487(1):253–258.
  • Caterina MJ, Rosen TA, Tominaga M, et al. A capsaicin-receptor homologue with a high threshold for noxious heat. Nature. 1999;398:436–441.
  • Schifferdecker B, Merchán J, Ahmar C, et al. Endovascular treatment of septic thrombophlebitis: a case report of a rare complication and a review of the literature. Vasc Med. 2009;14:47–50.
  • Allen BW, Bentley TP Lemierre syndrome. (Updated 2018 Oct. 27) In: StatPealrs. StatPearls Publishing, Treasure Island, FL (2018) [cited 2020 Mar 01]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499846/
  • Chirinos JA, Garcia J, Alcaide ML, et al. Septic thrombophlebitis: diagnosis and management. Am J Cardiovasc Drugs. 2006;6(1):9–14.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.